Absolute Bioavailability of Vemurafenib in Patients With BRAFV600 Mutation–Positive Malignancies
Sign Up to like & getrecommendations! Published in 2020 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.773
Abstract: Vemurafenib is a BRAF kinase inhibitor indicated for the treatment of patients with BRAFV600 mutation–positive unresectable or metastatic melanoma and Erdheim‐Chester disease. This phase 1, open‐label, single‐arm study was designed to estimate absolute bioavailability of… read more here.
Keywords: mutation positive; bioavailability; absolute bioavailability; patients brafv600 ... See more keywords
Delineation of LZTR1 mutation-positive patients with Noonan syndrome and identification of LZTR1 binding to RAF1–PPP1CB complexes
Sign Up to like & getrecommendations! Published in 2018 at "Human Genetics"
DOI: 10.1007/s00439-018-1951-7
Abstract: RASopathies are a group of developmental disorders caused by mutations in genes that regulate the RAS/MAPK pathway and include Noonan syndrome (NS), Costello syndrome, cardiofaciocutaneous syndrome and other related disorders. Whole exome sequencing studies recently… read more here.
Keywords: raf1 ppp1cb; noonan syndrome; mutation positive; ppp1cb ... See more keywords
Prognostic value of epidermal growth factor receptor mutations and histologic subtypes with lung adenocarcinoma
Sign Up to like & getrecommendations! Published in 2018 at "Medical Oncology"
DOI: 10.1007/s12032-018-1082-y
Abstract: The epidermal growth factor receptor (EGFR) mutation status has become one of the most important factors in the treatment of non-small cell lung cancer. However, the relationship between EGFR mutation and the histologic subtype of… read more here.
Keywords: egfr mutation; mutation positive; epidermal growth; adenocarcinoma ... See more keywords
Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050).
Sign Up to like & getrecommendations! Published in 2021 at "Lung cancer"
DOI: 10.1016/j.lungcan.2021.02.025
Abstract: OBJECTIVES To compare efficacy and safety of dacomitinib versus gefitinib as first-line therapy for EGFR mutation-positive advanced NSCLC in Asian patients enrolled in the ongoing ARCHER 1050 trial. MATERIALS AND METHODS In this ongoing, randomized,… read more here.
Keywords: egfr mutation; first line; mutation positive; asian patients ... See more keywords
T790M mutation positive squamous cell carcinoma transformation from EGFR-mutated lung adenocarcinoma after low dose erlotinib: A case report and literature review
Sign Up to like & getrecommendations! Published in 2022 at "Medicine"
DOI: 10.1097/md.0000000000029682
Abstract: Rationale: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are widely used for the treatment of EGFR mutation positive advanced nonsmall cell lung cancer (NSCLC); however, acquired resistance is known to develop during these… read more here.
Keywords: cell; mutation; treatment; transformation ... See more keywords
Long‐term response to afatinib in an elderly patient with uncommon epidermal growth factor receptor mutation‐positive lung adenocarcinoma
Sign Up to like & getrecommendations! Published in 2021 at "Thoracic Cancer"
DOI: 10.1111/1759-7714.13869
Abstract: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors are the standard treatment for patients with non‐small cell lung cancer (NSCLC) harboring EGFR mutations. Uncommon mutations, excluding exon 19 deletions and exon 21 L858R, comprise 7%–23%… read more here.
Keywords: afatinib treatment; mutation positive; treatment; epidermal growth ... See more keywords
Retrospective analysis of independent predictors of progression‐free survival in patients with EGFR mutation‐positive advanced non‐small cell lung cancer receiving first‐line osimertinib
Sign Up to like & getrecommendations! Published in 2022 at "Thoracic Cancer"
DOI: 10.1111/1759-7714.14608
Abstract: Clinically measurable factors affecting the progression‐free survival (PFS) of patients receiving osimertinib as first‐line therapy for epidermal growth factor receptor (EGFR) mutation‐positive advanced non‐small cell lung cancer (NSCLC) have not yet been established. read more here.
Keywords: free survival; progression free; first line; egfr mutation ... See more keywords
Precision targeted therapy for EGFR mutation‐positive NSCLC: Dilemmas and coping strategies
Sign Up to like & getrecommendations! Published in 2023 at "Thoracic Cancer"
DOI: 10.1111/1759-7714.14858
Abstract: The most common driver gene mutation in patients with non‐small‐cell lung cancer (NSCLC) is an epidermal growth factor receptor (EGFR) mutation. With the introduction of EGFR‐tyrosine kinase inhibitors, the treatment prospects and prognosis of NSCLC… read more here.
Keywords: therapy egfr; targeted therapy; egfr mutation; mutation ... See more keywords
Emergence of Pituitary Adenoma in a Child during Surveillance: Clinical Challenges and the Family Members' View in an AIP Mutation-Positive Family
Sign Up to like & getrecommendations! Published in 2018 at "International Journal of Endocrinology"
DOI: 10.1155/2018/8581626
Abstract: Introduction Germline aryl hydrocarbon receptor-interacting protein (AIP) mutations are responsible for 15–30% of familial isolated pituitary adenomas (FIPAs). We report a FIPA kindred with a heterozygous deletion in AIP, aiming to highlight the indications and… read more here.
Keywords: aip mutation; mutation positive; pituitary adenoma; family ... See more keywords
5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation–Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study
Sign Up to like & getrecommendations! Published in 2021 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-21-0809
Abstract: Purpose: The randomized phase III coBRIM study (NCT01689519) demonstrated improved progression-free survival (PFS) and overall survival (OS) with addition of cobimetinib to vemurafenib compared with vemurafenib in patients with previously untreated BRAFV600 mutation–positive advanced melanoma.… read more here.
Keywords: advanced melanoma; cobimetinib plus; plus vemurafenib; brafv600 mutation ... See more keywords
Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): an open-label, non-randomized, multicenter, phase IV clinical trial
Sign Up to like & getrecommendations! Published in 2018 at "BMC Cancer"
DOI: 10.1186/s12885-018-4283-z
Abstract: BackgroundErlotinib is approved for the first line treatment of epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer. Since the number of prospective studies in Caucasian patients treated in routine clinical setting is limited… read more here.
Keywords: lung adenocarcinoma; egfr mutation; first line; mutation positive ... See more keywords